Our researchers are constantly looking for medicines that can offer a solution for seriously ill patients. Clinical studies are essential for the development of these innovative medicines. In 2023, 29 Amgen studies took place in 63 different healthcare institutions in the Netherlands. A total of 1,580 patients were enrolled, of which 762 were new patients.

Do you want to know which studies? More information about Amgen's ongoing studies can be found on the www.clinicaltrials.gov website.

Investing in clinical trials organized by others

In addition to its own studies, Amgen also invests in third-party clinical trials. In 2023, these were 16 so-called Investigator Sponsored Studies (ISS), including DRUP, which stands for Drug Rediscovery Protocol. In DRUP, cancer patients who have little or no prospects are given medication that is actually intended for other types of cancer. It is usually too expensive to investigate whether these drugs also have an effect on other types of cancer, but due to the collaboration with hospitals and amongst others Amgen can now do this.

More information about our ISS studies can be found at:
https://www.amgeniss.com/

Relevant links:
www.amgen.nl/science/klinisch-onderzoek-in-nederland/
www.clinicaltrials.gov
https://www.amgeniss.com/